Cataract

Ambulatory surgical centers are freestanding health care facilities that specialize in providing surgical and diagnostic procedures, not requiring an overnight stay.

Cationic emulsion drops are characterized by their ability to retain cyclosporine A on the ocular surface.

Italian investigators reported that ocular surface conditions such as dry eye disease are key factors in perioperative outcomes, even when patients achieve 20/20 vision.

Monofocal IOLs, along with advanced phacoemulsification technology, offer tailored solutions.

Shameema Sikder, MD; and T. Y. Alvin Liu, MD, highlight the technology’s role in bridging challenges and successes for clinical practice.

The state-of-the-art facility more than doubles the institute’s footprint, enhancing patient care, research, and education.

Sonia H. Yoo, MD, a cornea, cataract, and refractive surgery specialist and a member of the planning committee for the EnVision Summit, highlights a session focused on the latest advancements in lens implant technologies, refractive procedures, and imaging innovations. The summit will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

From easing fears to improving mood, a recent study explores how music transforms the surgical experience for both patients and health care teams.

Through its ophthalmic program, Mercy Ships provides critical eye surgeries and trains local professionals, ensuring sustainable eye care for the future.

Lana Rifkin, MD, a uveitis specialist at Ophthalmic Consultants of Boston, shared insights into her work and her role as committee chair of the uveitis section for the upcoming EnVision Summit, which will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

According to the company, VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieved its primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery.

HelpMeSee’s Mazava Project trains general practitioners in Madagascar to perform cataract surgeries, addressing the country’s high rate of avoidable blindness. Trainees gain proficiency through simulation-based learning and live surgeries, improving access to eye care in remote areas.

Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with Ophthalmology Times, Randall Olson, MD, lead author and a Distinguished Professor at the University of Utah, Chair of the Department of Ophthalmology and Visual Sciences, and CEO of the John A. Moran Eye Center, discusses the ongoing research.

Program director and co-founder Bonnie An Henderson, MD, sits down with Ophthalmology Times to talk about how the annual conference is a unique blend of cutting-edge science, professional growth, and community. The 2025 conference will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

HelpMeSee has partnered with new initiatives to address the global cataract blindness crisis, focusing on empowering women in low- and middle-income countries. Through training and education, the organization aims to reduce gender inequality and improve socioeconomic outcomes worldwide.

HelpMeSee has partnered with Empowered, an educational series hosted by Meg Ryan, to spotlight the cataract blindness crisis, its socioeconomic impacts, and gender inequality issues. The episode emphasizes simulation-based surgical training advancements, expanding cataract care access for underserved populations and fostering equitable healthcare solutions.

Analysis highlights discrepancies between adult, pediatric cataract procedures.

The integration of artificial intelligence in laser cataract technology is shifting the paradigm for the future of cataract surgery and is driving increased precision and improved outcomes for patients.

George O. Waring, IV, MD, provides insights from an on-demand poster as part of the annual American Academy of Ophthalmology taking place in Chicago, Illinois. This poster was titled, "Two-Year Clinical Feasibility Trial Outcomes for a Dual-Optic IOL System for the Treatment of Presbyopia and Cataract."

Investigators conducted a retrospective clinical database study that covered 12 years to quantify the risk of PCR in the second eye after PCR developed in the first eye during cataract surgery.

According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to-moderate cataracts, by penetrating the eye to reduce lens clouding, the main cause for cataracts.

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets.

MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.

A collaborative model not only enhances the post-cataract experience but also paves the way for a future where refractive outcomes are accessible to all, regardless of the surgeon's specialty.

The Gni instrument technology represents a significant innovation in ophthalmic surgery, particularly in cataract procedures, according to Gulani.

According to a team of researchers at the National Institutes of Health, their findings in animals suggest a surgery-free treatment for cataracts.

The drop improves vision by breaking up degraded protein complexes that cause lens clouding

The device features real-time feedback and other features, allowing residents to hone their skills and expand options for practicing one of the most needed procedures in the country.